Vertex Pharmaceuticals Incorporated (FRA:VX1)

Market Cap	104.22B -11.0%
Revenue (ttm)	10.22B +8.9%
Net Income	3.37B
EPS	13.05
Shares Out	n/a
PE Ratio	30.95
Forward PE	24.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	64
Open	423.95
Previous Close	426.55
Day's Range	423.85 - 423.95
52-Week Range	313.75 - 475.00
Beta	n/a
RSI	51.69
Earnings Date	May 4, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,400
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VX1

Financial Performance

Financial numbers in USD